首页> 外文期刊>Cureus. >Isotretinoin Use and Risk of Depression in Acne Vulgaris Patients in Riyadh, Saudi Arabia
【24h】

Isotretinoin Use and Risk of Depression in Acne Vulgaris Patients in Riyadh, Saudi Arabia

机译:在沙特阿拉伯利雅得的痤疮寻常患者患者的异丙替税素使用和抑郁风险

获取原文
获取外文期刊封面目录资料

摘要

Background The association between isotretinoin administration and depression in acne patients remains controversial. We aim to estimate the prevalence of depression among patients with acne vulgaris before and after treatment with isotretinoin in Riyadh, Saudi Arabia. Methods This was a prospective study on patients?attending the King Khalid University Hospital (KKUH),?a?tertiary?institution, who were prescribed isotretinoin for the treatment of acne vulgaris for the first time. The Beck Depression Inventory (BDI) was used to screen for depressive symptoms. Results A total of 179 patients were included in the study. The patients were then divided into two groups based on the treatment modality that they received: one group taking isotretinoin and the other treatment?group who used other medications, including Retin-A (tretinoin) and Tazorac (tazarotene). A total of 119 patients were in the isotretinoin group with 91.6%, 2.5%, 1.7%, and 3.4% of those patients having a normal mood, mild depression, moderate depression, and severe depression scores before starting isotretinoin treatment, respectively. After three months of treatment, 94.1%, 1.7%, 0.8%, and 2.5% of patients had normal mood, mild depression, moderate depression, and severe depression, respectively. Meanwhile, after six months of treatment, 95.8%, 0.8%, 0%, and 1.7% of patients had normal mood, mild depression, moderate depression, and severe depression, respectively. The mean BDI score at the baseline was 3.31 ± 6.98 for isotretinoin and 3.17 ± 6.27 for other treatments. Compared to the baseline, patients using the isotretinoin showed a significant reduction in depression scores at three months (2.64 ± 6.17; p-value 0.001), six months (1.99 ± 5.08; p-value 0.001), and across all follow-up points (p-value 0.001). Similar results were also estimated for the other treatment group, including Retin-A (tretinoin), adapalene, benzoyl peroxide, and doxycycline; however, no significant difference was noticed between the two groups (p-value = 0.885). Conclusion Isotretinoin treatment for acne does not appear to be associated with a statistically significant increased risk of depression in our population.?Therefore, more studies are needed to understand this reflection in Saudi Arabia.
机译:背景技术在痤疮患者中的异黄素蛋白蛋白给药和抑郁症仍存在争议。我们的目标是估计在沙特阿拉伯利雅得的伊斯托替税素治疗前后寻常痤疮患者的抑郁症患者。方法这是对患者的前瞻性研究?参加哈立德大学医院(kkuh),?a?tertiary?机构,他是第一次为痤疮寻常治疗痤疮的癌症。 Beck抑郁库存(BDI)用于筛选抑郁症状。结果共有179名患者纳入该研究。然后将患者分为两组,基于他们所接受的治疗方式:一组服用异丙替税素和其他治疗方法?使用其他药物的群体,包括视黄菌(Tretinoin)和Tazorac(Tazarotene)。同甲丙酸锡中共有119名患者,分别在开始同甲藻治疗前分别为91.6%,2.5%,1.7%和3.4%的患者患有正常情绪,轻度抑郁,中度抑郁和严重的抑郁症。经过三个月的治疗后,94.1%,1.7%,0.8%和2.5%的患者分别具有正常的情绪,轻度抑郁,中度抑郁和严重抑郁症。同时,经过六个月的治疗后,95.8%,0.8%,0%和1.7%的患者分别具有正常的情绪,轻度抑郁,中度抑郁和严重抑郁症。基线的平均BDI评分为isotretinoin的3.31±6.98,适用于3.17±6.27,适用于其他治疗。与基线相比,使用异滴基蛋白的患者在三个月内显示出抑郁症分数的显着降低(2.64±6.17; p值<0.001),六个月(1.99±5.08; p值<0.001),以及所有后续点(p值<0.001)。其他治疗组还估计了类似的结果,包括视黄硅-A(维甲酯),阿巴平,过氧化苯甲酰和强霉素;然而,两组之间没有发现显着差异(p值= 0.885)。结论痤疮的异丙替税素治疗与我们的人口抑郁症的风险似乎没有相关。因此,需要更多的研究来了解沙特阿拉伯的反思。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号